• Cat-intel
  • MedIntelliX
  • Resources
  • About Us
  • Request Free Sample ×

    Kindly complete the form below to receive a free sample of this Report

    Leading companies partner with us for data-driven Insights

    clients tt-cursor
    Hero Background

    Transient Ischemic Attack Market

    ID: MRFR/Pharma/3590-CR
    226 Pages
    Rahul Gotadki
    July 2019

    Transient Ischemic Attack Market Research Report Information by Diagnosis (Imaging Techniques), Treatment (Surgery and Drugs), Age Groups (0–18 years and above), End-User and Region (Americas, Europe, Asia-Pacific and the Middle East & Africa) - Forecast till 2035

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Transient Ischemic Attack Market Infographic
    Purchase Options

    Transient Ischemic Attack Market Summary

    The Global Transient Ischemic Attack Market is projected to grow from 0.12 USD Billion in 2024 to 0.38 USD Billion by 2035.

    Key Market Trends & Highlights

    Transient Ischemic Attack Key Trends and Highlights

    • The market is expected to experience a compound annual growth rate (CAGR) of 11.0% from 2025 to 2035.
    • By 2035, the market valuation is anticipated to reach 0.38 USD Billion, indicating robust growth potential.
    • In 2024, the market is valued at 0.12 USD Billion, reflecting the current demand for TIA management solutions.
    • Growing adoption of advanced diagnostic technologies due to increasing awareness of transient ischemic attacks is a major market driver.

    Market Size & Forecast

    2024 Market Size 0.12 (USD Billion)
    2035 Market Size 0.38 (USD Billion)
    CAGR (2025-2035) 11.0%

    Major Players

    Koninklijke Philips NV (Netherlands), Stryker Corporation (US), Johnson & Johnson Services Inc (US), Boston Scientific Corporation (US), Sanofi (France), Bayer AG (Germany), Pfizer Inc (US), Siemens AG (US), F. Hoffmann-La Roche AG (Switzerland), GE Healthcare (UK), Penumbra Inc (California), Medtronic PLC (Ireland), Abbott Laboratories (US), Merck & Co., Inc (US), Boehringer Ingelheim GmbH (Germany)

    Transient Ischemic Attack Market Drivers

    Aging Population

    The demographic shift towards an aging population is a crucial factor driving the Global Transient Ischemic Attack Market Industry. As individuals age, the risk of cerebrovascular diseases, including TIAs, escalates. The United Nations projects that by 2030, the global population aged 60 years and older will reach 1.4 billion, creating a larger cohort susceptible to TIAs. This demographic trend necessitates enhanced healthcare services and interventions tailored to older adults, thereby fostering market expansion. The increasing burden of TIAs among the elderly population underscores the importance of developing targeted therapies and preventive measures.

    Rising Incidence of Stroke

    The increasing prevalence of stroke globally is a pivotal driver for the Global Transient Ischemic Attack Market Industry. As per recent health statistics, stroke remains one of the leading causes of morbidity and mortality worldwide. The World Health Organization indicates that approximately 15 million people suffer from stroke annually, with a significant portion experiencing transient ischemic attacks as precursors. This alarming trend underscores the necessity for enhanced diagnostic and therapeutic interventions, thereby propelling market growth. The Global Transient Ischemic Attack Market is projected to reach 0.12 USD Billion in 2024, reflecting the urgent need for effective management strategies.

    Market Trends and Projections

    The Global Transient Ischemic Attack Market Industry is witnessing notable trends that indicate a robust growth trajectory. Projections suggest that the market will expand from 0.12 USD Billion in 2024 to 0.38 USD Billion by 2035, reflecting a compound annual growth rate of 11.0% from 2025 to 2035. This growth is driven by various factors, including advancements in medical technology, increased awareness, and an aging population. The market dynamics are influenced by the evolving healthcare landscape, necessitating continuous adaptation by stakeholders to meet the demands of TIA management.

    Regulatory Support and Funding

    Government initiatives and regulatory support play a vital role in shaping the Global Transient Ischemic Attack Market Industry. Various health authorities are implementing policies aimed at improving stroke care and funding research for innovative treatments. For example, the National Institutes of Health in the United States allocates substantial resources to stroke research, which indirectly benefits TIA management. Such funding encourages the development of new therapies and technologies, thereby enhancing patient care. This supportive regulatory environment is expected to facilitate market growth, as stakeholders are more inclined to invest in TIA-related innovations.

    Increased Awareness and Education

    Growing awareness regarding transient ischemic attacks and their implications is significantly influencing the Global Transient Ischemic Attack Market Industry. Public health campaigns and educational initiatives by health organizations aim to inform individuals about the symptoms and risks associated with TIAs. This heightened awareness encourages early medical intervention, which is essential for preventing subsequent strokes. As a result, healthcare systems are increasingly prioritizing TIA management, leading to a surge in demand for related services and products. The market is expected to experience a compound annual growth rate of 11.0% from 2025 to 2035, driven by these educational efforts.

    Advancements in Medical Technology

    Technological innovations in medical devices and diagnostic tools are transforming the landscape of the Global Transient Ischemic Attack Market Industry. The advent of portable imaging technologies and telemedicine solutions facilitates timely diagnosis and treatment, which is crucial for TIA patients. For instance, advanced MRI techniques enable rapid identification of ischemic episodes, thereby improving patient outcomes. Furthermore, the integration of artificial intelligence in predictive analytics is enhancing risk stratification for TIA patients. These advancements not only improve clinical efficacy but also contribute to the anticipated market growth, with projections indicating a rise to 0.38 USD Billion by 2035.

    Key Companies in the Transient Ischemic Attack Market market include

    Future Outlook

    Transient Ischemic Attack Market Future Outlook

    The Global Transient Ischemic Attack Market is projected to grow at an 11.0% CAGR from 2024 to 2035, driven by advancements in diagnostics, increasing awareness, and enhanced treatment options.

    New opportunities lie in:

    • Develop AI-driven diagnostic tools to improve early detection of TIAs.
    • Invest in telehealth solutions for remote monitoring and patient management.
    • Create targeted therapies focusing on high-risk populations to enhance treatment efficacy.

    By 2035, the market is expected to achieve substantial growth, reflecting advancements in treatment and increased patient engagement.

    Market Segmentation

    Transient Ischemic Attack Market, by Region

    • Americas
    • North America
    • US
    • Canada
    • Latin America
    • Europe
    • Western Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of Western Europe
    • Eastern Europe
    • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
    • Middle East & Africa
    • Middle East
    • Africa

    Transient Ischemic Attack Market, by End-User

    • Hospitals & Clinics
    • Diagnostic Centers
    • Research Laboratories

    Transient Ischemic Attack Market, by Diagnosis

    • Imaging Techniques
    • Computed Tomography (CT) scan
    • Carotid Duplex Scanning
    • Magnetic Resonance Imaging
    • Echocardiography            

    Transient Ischemic Attack Market, by Treatment

    • Surgery
    • Drugs
    • Antithrombotic agents
    • Antiplatelets
    • Clopidogrel
    • Aspirin
    • Heparins
    • ENOXAPARIN
    • DALTEPARIN
    • Fibrinolytics
    • Tenecteplase

    Transient Ischemic Attack Market, by Age Groups

    • 0–18 years
    • 19–40 years (Millennial)
    • 41–60 years
    • 60+ years

    Report Scope

    Attribute/Metric Details
    Market Size 2030  USD 0.29 Billion 2032
    Compound Annual Growth Rate (CAGR) 9.34% 2032
    Base Year 2021
    Market Forecast Period 2024-2032
    Historical Data 2018 - 2021
    Market Forecast Units Value (USD Million)
    Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
    Segments Covered Product, technology, application, and end-users.
    Geographies Covered Americas, Europe, Asia Pacific and the Middle East and Africa
    Countries Covered China, Japan, India, Australia, South Korea, Australia, Rest of Asia-Pacific
    Key Companies Profiled Koninklijke Philips NV (Netherlands), Stryker Corporation (US), Johnson & Johnson Services Inc (US), Boston Scientific Corporation (US), Sanofi (France), Bayer AG (Germany), Pfizer Inc (US), Siemens AG (US), F. Hoffmann-La Roche AG (Switzerland), GE Healthcare (UK), Penumbra Inc (California), Medtronic PLC (Ireland), Abbott Laboratories (US), Merck & Co., Inc (US), and Boehringer Ingelheim GmbH (Germany).
    Key Market Opportunities Key market opportunities for the Transient Ischemic Attack market include the development of advanced diagnostic tools, innovative treatment options, and personalized medicine approaches to improve early detection and patient outcomes.
    Key Market Dynamics   The key market dynamics for the transient ischemic attack (TIA) market include increasing incidence rates, advances in diagnostic and therapeutic technologies, growing awareness and early intervention, and substantial investment in research and development.

    Market Highlights

    Author
    Rahul Gotadki
    Assistant Manager

    He holds an experience of about 7+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. In addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives

    Leave a Comment

    FAQs

    At what CAGR is the global transient ischemic attack market projected to grow in the forecast period (2024-2032)?

    Transient ischemic attack market projected to grow at approximately 9.24% CAGR during the assessment period (2024-2032).

    How much is the global transient ischemic attack market worth in the future?

    The valuation of the global transient ischemic attack market is estimated to increase to USD 0.29 Billion by the end of 2032.

    What are the major tailwinds pushing the growth of the global transient ischemic attack market?

    Rising need for better treatment due to the increasing prevalence of neurological disorders and increasing R&D investments in biotechnology and pharmaceutical sectors are major tailwinds pushing the growth of the global transient ischemic attack market.

    Which region holds the largest share in the global transient ischemic attack market?

    North America holds the largest share in the global transient ischemic attack market, followed by Europe and the Asia Pacific, respectively.

    Who are the top players in the global transient ischemic attack market?

    EnteroMedics Inc. (U.S.), ElectroCore Medical LLC (U.S.), LivaNova PLC (U.K), Cyberonics, Inc. (US), NeuroMetrix, Inc.(U.S.), Boston Scientific Corporation (US), Inspire Medical Systems Inc.(U.S.), Electrical Geodesics Inc. (U.S.), ImThera Medical (U.S.), Nihon Kohden Corporation (Japan), Esaote (Italy), Masimo Corporation (U.S.), and Hologic (U.S.), are some of the top players operating in the global transient ischemic attack market.

    Download Free Sample

    Kindly complete the form below to receive a free sample of this Report

    Case Study
    Chemicals and Materials